Apolipoprotein B (apoB) truncation-specifying mutations cause familial hypobetalipoproteinemia (FHBL). Lipoprotein kinetics studies have shown that production rates of apoB-100 are reduced by 70-80% in heterozygous FHBL humans, instead of the expected 50%. To develop suitable mouse models to study the underlying mechanism, apoB-38.9-only (Apob38.9/38.9) mice were crossbred with Apobec-1 knockout (Apobec-1-/-) mice or apoB-100-only (Apob100/100) mice to produce two lines of apoB-38.9 heterozygous mice that produce only apoB-38.9 and apoB-100, namely Apobec-1-/- /Apob38.9/+ and Apob38-9/100 mice. In vivo rates of apoB-100 secretion were measured using [35S]Met/Cys to label proteins and Triton WR-1339 to block apoB-100 VLDL lipolysis/uptake. Rates of secretion were reduced by 80%, rather than the expected 50%, in both Apobec-1-/- /Apob38-9/+ and Apob38-9/100 mice compared with those of the respective Apobec-1-/- /Apob +/+ and Apob100/100 control mice. Continuous labeling and pulse-chase experiments in primary hepatocyte cultures revealed that rates of apoB-100 synthesis by Apobec-1-/- /Apob38.9/+ and Apob38.9/100 hepatocytes were reduced to the expected 50% of those of the respective controls, but the efficiency of secretion of apoB-100 was significantly lower in apoB-38.9 heterozygous hepatocytes. The greater-than-expected decreases in apoB-100 production rates of FHBL heterozygous humans appear to be attributable to a defect in secretion rather than in the synthesis of apoB-100 from the unaffected apoB allele.

Original languageEnglish
Pages (from-to)155-163
Number of pages9
JournalJournal of lipid research
Issue number1
StatePublished - Jan 2004


  • Animal model
  • Gene targeting
  • VLDL secretion


Dive into the research topics of 'Hepatic secretion of apoB-100 is impaired in hypobetalipoproteinemic mice with an apoB-38.9-specifying allele'. Together they form a unique fingerprint.

Cite this